Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $25.40.

A number of brokerages have issued reports on GENB. Wall Street Zen raised Generate Biomedicines from a “sell” rating to a “hold” rating in a research note on Saturday. Morgan Stanley boosted their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Finally, HC Wainwright upped their price objective on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th.

Generate Biomedicines Price Performance

GENB stock opened at $13.40 on Monday. The stock’s 50-day moving average is $14.34. The company has a market cap of $1.72 billion and a P/E ratio of -12.52. Generate Biomedicines has a 52 week low of $11.00 and a 52 week high of $18.18.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.